Pulmonary Arterial Hypertension in Congenital Heart Diseases

ABSTRACT

Pulmonary hypertension complicates the course of many children and adults with congenital heart diseases (CHDs). The increase in pulmonary pressure associated with CHD is secondary to either increased pulmonary blood flow or increased postcapillary pressures. Pulmonary arterial hypertension is in the vast majority associated with congenital cardiac shunts. Despite major advances in the understanding of the regulation of the pulmonary vascular bed and the pulmonary endothelial lesions leading to pulmonary vascular disease, despite the advances in surgical repair and the discovery of potential therapies in the pre- and postoperative period, pulmonary hypertension still carries a significant mortality and morbidity in patients with CHD. The recent introduction of targeted therapies in other forms of pulmonary arterial hypertension has led to a renewed interest in pulmonary hypertension associated with CHD and this particularly for the most advanced form, the so-called Eisenmenger syndrome (ES). This review summarizes the current knowledge on pulmonary hypertension associated with CHD, focusing on the pathophysiology and treatment of ES.

KEYWORDS

Hypertension - pulmonary - heart defect - congenital - Eisenmenger syndrome

REFERENCES

• 1 Beghetti M. Congenital heart disease and pulmonary hypertension.  Rev Port Cardiol. 2004;  23 273-281
• 2 Granton J T, Rabinovitch M. Pulmonary arterial hypertension in congenital heart disease.  Cardiol Clin. 2002;  20 441-457, vii
• 3 Kidd L, Driscoll D J, Gersony W M et al.. Second natural history study of congenital heart defects: results of treatment of patients with ventricular septal defects.  Circulation. 1993;  87(2, Suppl) I38-I51
• 4 Diller G P, Dimopoulos K, Broberg C S et al.. Presentation, survival prospects, and predictors of death in Eisenmenger syndrome: a combined retrospective and case-control study.  Eur Heart J. 2006;  27 1737-1742
• 5 Haworth S G. Pulmonary vascular disease in different types of congenital heart disease: implications for interpretation of lung biopsy findings in early childhood.  Br Heart J. 1984;  52 557-571
• 6 Galiè N, Torbicki A, Barst R et al.. Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology.  Eur Heart J. 2004;  25 2243-2278
• 7 Diller G P, Gatzoulis M A. Pulmonary vascular disease in adults with congenital heart disease.  Circulation. 2007;  115 1039-1050
• 8 Simonneau G, Galiè N, Rubin L J et al.. Clinical classification of pulmonary hypertension.  J Am Coll Cardiol. 2004;  43(12, Suppl S) 5S-12S
• 9 Galie N, Manes A, Palazzini M et al.. Management of pulmonary arterial hypertension associated with congenital systemic-to-pulmonary shunts and Eisenmenger's syndrome.  Drugs. 2008;  68 1049-1066
• 10 van Albada M E, Berger R M. Pulmonary arterial hypertension in congenital cardiac disease—the need for refinement of the Evian-Venice classification.  Cardiol Young. 2008;  18 10-17
• 11 Rabinovitch M, Bothwell T, Hayakawa B N et al.. Pulmonary artery endothelial abnormalities in patients with congenital heart defects and pulmonary hypertension: a correlation of light with scanning electron microscopy and transmission electron microscopy.  Lab Invest. 1986;  55 632-653
• 12 Rabinovitch M. Pulmonary hypertension: pathophysiology as a basis for clinical decision making.  J Heart Lung Transplant. 1999;  18 1041-1053
• 13 Haworth S G. Pulmonary vascular disease in ventricular septal defect: structural and functional correlations in lung biopsies from 85 patients, with outcome of intracardiac repair.  J Pathol. 1987;  152 157-168
• 14 Newfeld E A, Paul M M, Muster A J, Idriss F S. Pulmonary vascular disease in complete transposition of the great arteries: a study of 200 patients.  Am J Cardiol. 1974;  34 75-82
• 15 Eisenmenger V. Die angeborenen defects des kammerscheidewand des herzen.  Z Klin Med. 1897;  32 1-28
• 16 Wood P. The Eisenmenger syndrome or pulmonary hypertension with reversed central shunt, I.  BMJ. 1958;  46 701-709
• 17 Daliento L, Somerville J, Presbitero P et al.. Eisenmenger syndrome: factors relating to deterioration and death.  Eur Heart J. 1998;  19 1845-1855
• 18 Diller G P, Dimopoulos K, Okonko D et al.. Exercise intolerance in adult congenital heart disease: comparative severity, correlates, and prognostic implication.  Circulation. 2005;  112 828-835
• 19 Pietra G G. The pathology of pulmonary hypertension. In: Rubin LJ, Rich S Primary Pulmonary Hypertension. New York; Marcel Dekker 1997: 19-61
• 20 Vongpatanasin W, Brickner M E, Hillis L D, Lange R A. The Eisenmenger syndrome in adults.  Ann Intern Med. 1998;  128 745-755
• 21 Hopkins W E, Ochoa L L, Richardson G W, Trulock E P. Comparison of the hemodynamics and survival of adults with severe primary pulmonary hypertension or Eisenmenger syndrome.  J Heart Lung Transplant. 1996;  15(1 Pt 1) 100-105
• 22 Hopkins W E. The remarkable right ventricle of patients with Eisenmenger syndrome.  Coron Artery Dis. 2005;  16 19-25
• 23 Humbert M, Morrell N W, Archer S L et al.. Cellular and molecular pathobiology of pulmonary arterial hypertension.  J Am Coll Cardiol. 2004;  43(12, Suppl S) 13S-24S
• 24 Deanfield J, Thaulow E, Warnes C Task Force on the Management of Grown Up Congenital Heart Disease, European Society of Cardiology et al. Management of grown up congenital heart disease.  Eur Heart J. 2003;  24 1035-1084
• 25 Broberg C S, Ujita M, Prasad S et al.. Pulmonary arterial thrombosis in eisenmenger syndrome is associated with biventricular dysfunction and decreased pulmonary flow velocity.  J Am Coll Cardiol. 2007;  50 634-642
• 26 Berman E B, Barst R J. Eisenmenger's syndrome: current management.  Prog Cardiovasc Dis. 2002;  45 129-138
• 27 Stoica S C, McNeil K D, Perreas K et al.. Heart-lung transplantation for Eisenmenger syndrome: early and long-term results.  Ann Thorac Surg. 2001;  72 1887-1891
• 28 Adriaenssens T, Delcroix M, Van Deyk K, Budts W. Advanced therapy may delay the need for transplantation in patients with the Eisenmenger syndrome.  Eur Heart J. 2006;  27 1472-1477
• 29 Beghetti M, Black S M, Fineman J R. Endothelin-1 in congenital heart disease.  Pediatr Res. 2005;  57(5 Pt 2) 16R-20R
• 30 Galié N, Manes A, Branzi A. The endothelin system in pulmonary arterial hypertension.  Cardiovasc Res. 2004;  61 227-237
• 31 Galiè N, Beghetti M, Gatzoulis M A Bosentan Randomized Trial of Endothelin Antagonist Therapy-5 (BREATHE-5) Investigators et al. Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study.  Circulation. 2006;  114 48-54
• 32 Gatzoulis M A, Beghetti M, Galiè N BREATHE-5 Investigators et al. Longer-term bosentan therapy improves functional capacity in Eisenmenger syndrome: results of the BREATHE-5 open-label extension study.  Int J Cardiol. 2008;  127 27-32
• 33 Brun H, Thaulow E, Fredriksen P M, Holmstrom H. Treatment of patients with Eisenmenger's syndrome with Bosentan.  Cardiol Young. 2007;  17 288-294
• 34 Benza R L, Rayburn B K, Tallaj J A et al.. Efficacy of bosentan in a small cohort of adult patients with pulmonary arterial hypertension related to congenital heart disease.  Chest. 2006;  129 1009-1015
• 35 Schulze-Neick I, Gilbert N, Ewert R et al.. Adult patients with congenital heart disease and pulmonary arterial hypertension: first open prospective multicenter study of bosentan therapy.  Am Heart J. 2005;  150 716
• 36 Gatzoulis M A, Rogers P, Li W et al.. Safety and tolerability of bosentan in adults with Eisenmenger physiology.  Int J Cardiol. 2005;  98 147-151
• 37 Christensen D D, McConnell M E, Book W M, Mahle W T. Initial experience with bosentan therapy in patients with the Eisenmenger syndrome.  Am J Cardiol. 2004;  94 261-263
• 38 Diller G P, Dimopoulos K, Kaya M G et al.. Long-term safety, tolerability and efficacy of bosentan in adults with pulmonary arterial hypertension associated with congenital heart disease.  Heart. 2007;  93 974-976
• 39 D'Alto M, Vizza C D, Romeo E et al.. Long term effects of bosentan treatment in adult patients with pulmonary arterial hypertension related to congenital heart disease (Eisenmenger physiology): safety, tolerability, clinical, and haemodynamic effect.  Heart. 2007;  93 621-625
• 40 van Loon R L, Hoendermis E S, Duffels M G et al.. Long-term effect of bosentan in adults versus children with pulmonary arterial hypertension associated with systemic-to-pulmonary shunt: does the beneficial effect persist?.  Am Heart J. 2007;  154 776-782
• 41 Apostolopoulou S C, Manginas A, Cokkinos D V, Rammos S. Long-term oral bosentan treatment in patients with pulmonary arterial hypertension related to congenital heart disease: a 2-year study.  Heart. 2007;  93 350-354
• 42 Rosenzweig E B, Kerstein D, Barst R J. Long-term prostacyclin for pulmonary hypertension with associated congenital heart defects.  Circulation. 1999;  99 1858-1865
• 43 Fernandes S M, Newburger J W, Lang P et al.. Usefulness of epoprostenol therapy in the severely ill adolescent/adult with Eisenmenger physiology.  Am J Cardiol. 2003;  91 632-635
• 44 Frost A E, Quiñones M A, Zoghbi W A, Noon G P. Reversal of pulmonary hypertension and subsequent repair of atrial septal defect after treatment with continuous intravenous epoprostenol.  J Heart Lung Transplant. 2005;  24 501-503
• 45 Schwerzmann M, Zafar M, McLaughlin P R, Chamberlain D W, Webb G, Granton J. Atrial septal defect closure in a patient with “irreversible” pulmonary hypertensive arteriopathy.  Int J Cardiol. 2006;  110 104-107
• 46 Limsuwan A, Pienvichit P, Khowsathit P. Beraprost therapy in children with pulmonary hypertension secondary to congenital heart disease.  Pediatr Cardiol. 2005;  26 787-791
• 47 Ivy D D, Doran A K, Smith K J et al.. Short- and long-term effects of inhaled iloprost therapy in children with pulmonary arterial hypertension.  J Am Coll Cardiol. 2008;  51 161-169
• 48 Agapito A F, Sousa L, Oliveira J A, Feliciano J, Cacela D, Quininha J. Eisenmenger syndrome in the adult: experience with new drugs for the treatment of pulmonary hypertension.  Rev Port Cardiol. 2005;  24 421-431
• 49 Okyay K, Cemri M, Boyac B, Yalcn R, Cengel A. Use of long-term combined therapy with inhaled iloprost and oral sildenafil in an adult patient with eisenmenger syndrome.  Cardiol Rev. 2005;  13 312-314
• 50 Chau E M, Fan K Y, Chow W H. Effects of chronic sildenafil in patients with Eisenmenger syndrome versus idiopathic pulmonary arterial hypertension.  Int J Cardiol. 2007;  120 301-305
• 51 Garg N, Sharma M K, Sinha N. Role of oral sildenafil in severe pulmonary arterial hypertension: clinical efficacy and dose response relationship.  Int J Cardiol. 2007;  120 306-313
• 52 Mukhopadhyay S, Sharma M, Ramakrishnan S et al.. Phosphodiesterase-5 inhibitor in Eisenmenger syndrome: a preliminary observational study.  Circulation. 2006;  114 1807-1810
• 53 Lim Z S, Salmon A P, Vettukattil J J, Veldtman G R. Sildenafil therapy for pulmonary arterial hypertension associated with atrial septal defects.  Int J Cardiol. 2007;  118 178-182
• 54 Oechslin E, Kiowski W, Schindler R, Bernheim A, Julius B, Brunner-La Rocca H P. Systemic endothelial dysfunction in adults with cyanotic congenital heart disease.  Circulation. 2005;  112 1106-1112
• 55 Lunze K, Gilbert N, Mebus S et al.. First experience with an oral combination therapy using bosentan and sildenafil for pulmonary arterial hypertension.  Eur J Clin Invest. 2006;  36(Suppl 3) 32-38
• 56 Galiè N, Rubin L j, Hoeper M et al.. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial.  Lancet. 2008;  371 2093-2100